Cervarix™ Pregnancy Registry

for Cervarix™ Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant

The Cervarix Pregnancy Registry is active in the United Kingdom in collaboration with the UK Health Protection Agency (HPA). To participate in this registry: Registration should take place as early in the pregnancy as possible and prior to any knowledge of the pregnancy outcome. Healthcare providers are encouraged to notify the registry staff of ongoing pregnancies where exposure to the vaccine has already occurred.

UK Patients can be registered by either calling GlaxoSmithKline directly at 0800 221441 (UK toll-free) or by consulting the HPA website at http://www.hpa.org.uk.

UK Reports
GlaxoSmithKline UK
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

OR

GlaxoSmithKline Biologicals
Biologicals Clinical Safety and Pharmacovigilance
Rue de l’Institut 89
B-1330 Rixensart, Belgium
Fax: 32 2 656 8009 or 32 2 656 5116
Email: safety-vac ww/pharmbio/gsk@gsk

GlaxoSmithKline's Cervarix Pregnancy Registry is managed at:

Cervarix Pregnancy Registry
GlaxoSmithKline Biologicals
Biologicals Clinical Safety and Pharmacovigilance
Rue de l’Institut 89
B-1330 Rixensart, Belgium
Fax: 32 2 656 8009 or 32 2 656 5116
Email: safety-vac ww/pharmbio/gsk@gsk

Information collected at the time of registration includes date(s) of vaccine exposure, estimated date of delivery, and sufficient contact information to allow for follow-up of the subsequent pregnancy outcome. Measures are in place to protect patient confidentiality. If Registration is initiated from a consumer, permission is requested to obtain confirmation and follow-up from their health care provider. Around the patient’s estimated date of delivery, a short follow-up form is sent to the registering healthcare provider to report on the pregnancy course and outcome.

Additional resources: